Vaishali Pharma cash flow

·UnclassifiedChart ›
Latest FY26
Cash from operations
₹0.4cr−₹18.0 cr in FY25
Capital spending
₹0.5crNo figure a year before
Free cash flow
−₹0.0cr−₹18.0 cr in FY25
Cash from financing
₹4.6cr−75.1% on FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY23Mar 2023
Adjustments to reconcile profit — non-cash items
—0.60.50.5
—1.91.52.0
—0.1−0.1−1.3
—0.0−0.00.0
—0.2——
—2.1——
Changes in working capital
—1.4−4.4−2.4
—−6.4−2.54.9
—−2.1——
—−6.08.0−10.3
—0.0——
—7.6——
Cash from operating activities
5.45.4——
—−0.5——
—4.9−17.72.6
—0.5——
—−0.0——
—−4.0——
—0.4−18.01.1
Cash from investing activities
—0.5——
—5.1——
—0.0——
—0.10.10.6
—−0.0——
—−5.5−0.20.3
Cash from financing activities
—6.9——
—0.30.30.3
—−1.9——
—4.618.5−1.7
—−0.4——
—−0.40.3−0.4
——1.81.0
Reference items
4.24.1——
3.9%3.8%——
−0.0−0.0−18.01.1
—6.8——
−₹0.00−₹0.00−₹2.77₹0.17
—0.10×——
—0.5——
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

VAISHALI₹6.87

Vaishali Pharma Limited

· Unclassified
₹ CrorePeersTEMBOTOTALOSWALSEEDSGROBTEABEARDSELLHINDCONCROWNARTNIRMANMcap ₹44.8 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation0.5—0.50.6—
+ Finance Costs2.0—1.51.9—
+ Interest Income-1.3—-0.10.1—
+ Dividend Income0.0—-0.00.0—
+ Unrealised FX (Gain) / Loss———0.2—
+ Other Non-cash Items———2.1—
Changes in Working Capital
+ Inventories-2.4—-4.41.4—
+ Trade Receivables — Current4.9—-2.5-6.4—
+ Other Non-current Assets———-2.1—
+ Trade Payables — Current-10.3—8.0-6.0—
+ Other Current Liabilities———0.0—
+ Provisions — Current———7.6—
Cash from Operating Activities
Profit Before Tax (per I/S)———5.45.4
+ Total Adjustments (incl. Working Capital)———-0.5—
Cash from Operations (pre-tax)2.6—-17.74.9—
+ Interest Paid — Operating———0.5—
+ Dividends Received — Operating———-0.0—
+ Other Inflows / (Outflows) — Operating———-4.0—
Cash from Operating Activities1.1—-18.00.4—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)———0.5—
+ Acq of Subsidiaries / Businesses (net)———5.1—
+ Dividends Received — Investing———0.0—
+ Interest Received — Investing0.6—0.10.1—
+ Other Inflows / (Outflows) — Investing———-0.0—
Cash from Investing Activities0.3—-0.2-5.5—
Cash from Financing Activities
+ Proceeds from Borrowings———6.9—
+ Payment of Lease Liabilities0.3—0.30.3—
+ Other Inflows / (Outflows) — Financing———-1.9—
Cash from Financing Activities-1.7—18.54.6—
Net Changes in Cash (pre-FX)———-0.4—
Net Changes in Cash-0.4—0.3-0.4—
Closing Cash1.0—1.8——
Reference Items
EBITDA———4.14.2
EBITDA Margin %———3.783.92
Free Cash Flow (CFO − Capex)1.1—-18.0-0.0-0.0
Free Cash Flow to Equity———6.8—
Free Cash Flow per Basic Share0.17—-2.77-0.00-0.00
Cash Flow to Net Income———0.10—
Cash Paid for Interest———0.5—
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.